
Opus Genetics, Inc.: financial statements
Price
$3.99
November 20, 2026Market cap $386M
What Ploutos Investor adds for Opus Genetics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- A figure that did not match the numbers it is built from has been left out.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
-13.7% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $19M | $11M | $14M | -13.7% |
| Operating income | -$11M | -$62M | -$39M | |
| Net income | -$10.0M | -$58M | -$50M | |
| Earnings per share | -$0.46 | -$2.15 | -$0.80 | |
| Earnings per share, basic | -$0.46 | -$2.15 | -$0.80 | |
| Margins | ||||
| Operating margin | -55.5% | -564.7% | -271.9% | |
| Net margin | -52.4% | -523.4% | -349.3% | |
Financial statements
IRD's revenue, profits and cash flows from 2009 to 2022, 9 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Tax credits
+1.7 pts
Change in valuation allowance
-9.3 pts
State and local taxes
-6.8 pts
Fair-value remeasurements
-5.3 pts
Non-deductible expenses
-0.8 pts
Share-based compensation
-0.5 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
Effective tax rate by year
The tax rate IRD paid on its profit, from 2019 to 2022, 4 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Receivables and inventory against sales
In the quarter to Sep 30, 2026, sales were -63.1% on the same quarter a year earlier, and receivables -65.5%.
- a year earlier 86 days
- 80 days
Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.
The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
The tax part is not shown: a figure it needs is missing from the company's structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Opus Genetics's filings show?
These are Opus Genetics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did IRD have in 2025?
Opus Genetics had revenue of $14M and net income of -$50M in fiscal 2025, a net margin of -349.3%.
How much debt does IRD have?
On December 31, 2025 Opus Genetics had total assets of $50M, debt of $1.1M and shareholders' equity of $15M.
Where are the figures from?
From Opus Genetics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.